Fig 1: Knockdown of Igf2as reduces ERK activation in HepG2 cells. (A) Immunohistochemistry analysis demonstrated that the phosphorylation of ERK is reduced following knockdown of Igf2as. (B) Inhibition of Igf2as reduced the level of p-ERK. (C) Western blot demonstrating that the level ERK activation and a number of downstream signaling proteins were decreased following treatment with si-Igf2as. (D) Quantification of western blotting revealed that the levels of p-ERK/ERK, Bcl-2, Snal1 and p-Akt/Akt were reduced by Igf2as knockdown. *P<0.05, **P<0.01 vs. the NC. Igf2as, insulin-like growth factor 2 antisense 1; NC, negative control; si-Igfas, small interfering RNA targeting Igf2as; ERK, extracellular signal-regulated kinase, p-ERK, phosphorylated ERK; Bcl-2, B-cell lymphoma 2; Akt, protein kinase B; p-Akt, phosphorylated Akt; HCC, hepatocellular carcinoma.